HeimTTNP • NASDAQ
add
Titan Pharmaceuticals, Inc. common stock
Við síðustu lokun
3,72 $
Dagbil
3,62 $ - 3,76 $
Árabil
3,03 $ - 14,80 $
Markaðsvirði
3,44 m. USD
Meðalmagn
28,06 þ.
V/H-hlutf.
-
A/V-hlutfall
-
Aðalkauphöll
NASDAQ
Viðskiptafréttir
Fjármál
Rekstrarreikningur
Tekjur
Nettótekjur
| (USD) | des. 2024info | Breyting á/á |
|---|---|---|
Tekjur | — | — |
Rekstrarkostnaður | 666,00 þ. | -53,88% |
Nettótekjur | -790,00 þ. | 59,90% |
Hagnaðarhlutfall | — | — |
Hagnaður á hvern hlut | — | — |
EBITDA | -666,00 þ. | 65,46% |
Virkt skatthlutfall | — | — |
Efnahagsreikningur
Heildareignir
Heildarskuldir
| (USD) | des. 2024info | Breyting á/á |
|---|---|---|
Reiðufé og skammtímafjárfestingar | 2,83 m. | -58,12% |
Heildareignir | 2,92 m. | -63,85% |
Heildarskuldir | 483,00 þ. | -66,55% |
Eigið fé alls | 2,44 m. | — |
Útistandandi hlutabréf | 914,23 þ. | — |
Eiginfjárgengi | 1,39 | — |
Arðsemi eigna | -51,03% | — |
Ávöxtun eigin fjár | -58,72% | — |
Peningaflæði
Breyting á handbæru fé
| (USD) | des. 2024info | Breyting á/á |
|---|---|---|
Nettótekjur | -790,00 þ. | 59,90% |
Handbært fé frá rekstri | -506,00 þ. | 77,47% |
Reiðufé frá fjárfestingum | — | — |
Reiðufé frá fjármögnun | -62,00 þ. | -115,27% |
Breyting á handbæru fé | -568,00 þ. | 57,49% |
Frjálst peningaflæði | -193,25 þ. | 80,89% |
Um
Titan Pharmaceuticals, Inc. is a biopharmaceutical company based in San Francisco, CA, developing proprietary therapeutics primarily for treating central nervous system disorders. In September 2018, Titan Pharmaceuticals underwent an IPO wherein it raised $9.5 million in gross proceeds. In the same month, it also posted approximately $1.7 million in revenue, in large part drawn from its licensing for its European intellectual property rights for Probuphine to the Italian pharmaceutical company Molteni – a leading European opioid manufacturer and also a subsidiary of the German Pharmaceutical juggernaut Merck Group.
Titan's principal asset is Probuphine, a slow-release implant formulation of buprenorphine for the treatment of opioid addiction or chronic pain. FDA Approval was granted on 26 May 2016. It was licensed to Braeburn Pharmaceuticals for marketing and commercialization. Wikipedia
Stofnsett
1991
Höfuðstöðvar
Vefsvæði
Starfsfólk
4
